# Kangpinhui

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kangpinhui

- Industry: Retail
- Headquarters: Shanghai, China
- Website: www.kangpinhui.com
- Total disclosed funding: $15M
- Latest round: Series B (Mar 3, 2021)
- Investors on record: 5

## About

Kangpinhui is a health technology company that specializes in innovative health and wellness products, utilizing advanced technology to enhance user engagement and promote overall well-being.Founded in 2009, Kangpinhui operates from its headquarters in Shanghai, China. The company focuses on health technology solutions and has successfully completed a total of 3 deals. The most recent deal, a Series B funding round, occurred on March 3, 2021, raising RMB 100 million, primarily led by SBI Investment, with participation from Shanghai Chessboard Investment Management. The CEO of Kangpinhui is Yun Tao.Kangpinhui specializes in a range of innovative products and services designed to address specific needs within its target market. The company’s core offerings include health and wellness products that leverage advanced technology to promote user engagement and enhance overall well-being. These products aim to solve issues related to health management and preventive care, catering to a diverse clientele that includes both individual consumers and healthcare providers. Released over the past few years, these solutions have positioned Kangpinhui as a key player in the health technology sector, serving markets across Asia, particularly in regions like China and Southeast Asia, where demand for integrated health solutions is rapidly increasing. The customer base encompasses a mix of direct consumers who utilize these products for personal health, as well as business partnerships with healthcare institutions that integrate Kangpinhui’s offerings into their service models.Kangpinhui operates through a structured revenue model that emphasizes direct sales and partnerships within the healthcare ecosystem. Transactions typically occur through a combination of direct-to-consumer sales and business-to-business arrangements, where healthcare providers incorporate Kangpinhui’s products into their treatment offerings. This approach facilitates a steady revenue stream, as healthcare institutions purchase products in bulk while individual consumers can access offerings via subscription models or one-time purchases. The company’s flagship products are positioned to cater to various pricing tiers, allowing for flexibility in consumer engagement and broader market penetration. Through these structured transactions, Kangpinhui effectively captures a significant portion of the health and wellness market, reinforcing its presence in both the retail and professional healthcare sectors.Kangpinhui plans to leverage the RMB 100 million raised in its Series B funding round to support the development and launch of new health technology products. The company aims to introduce these products in the coming year, targeting specific markets in Southeast Asia to expand its reach. Recent funding efforts will be instrumental in enhancing product development capabilities and facilitating market entry strategies.

## Funding rounds

- Series B, Mar 3, 2021, $15M — SBI Investment, Shanghai Chessboard Investment Management
- Series B, Feb 5, 2020 — Gaorong Ventures
- Series A, Nov 20, 2017 — JJ Ventures, Long Z Investment

## Investors

- JJ Ventures (https://capitalatlas.ai/funds/jj-ventures) — Series A
- Long Z Investment (https://capitalatlas.ai/funds/long-z-investment) — Series A
- Gaorong Ventures (https://capitalatlas.ai/funds/gaorong-ventures) — Series B
- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Series B
- Shanghai Chessboard Investment Management — Series B